Compare Amgen, Inc. (AMGN) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Marathon Petroleum Corp — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Marathon Petroleum Corp trades at $285.51 (market cap $82.83B). The key difference: Amgen, Inc. is far larger — about 2.4× Marathon Petroleum Corp's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | MPC | |
|---|---|---|
Market Cap | $196.12B | $82.83B |
Sector | Health | Energy |
52-Week High | $388.16 | $283.74 |
52-Week Low | $271.18 | $158.59 |
Enterprise Value | $241.41B | $115.01B |
Dividend Yield | 2.77% | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Marathon Petroleum (MPC) trades at $283.74, up 0.16% with a bullish technical outlook supported by moving averages. The stock shows strong profitability with 27.92% ROE and attractive valuation metrics including P/E of 18.68 and P/S of 0.63. Recent earnings beat expectations in Q4 2025 and Q1 2026, while refining capacity constraints and Middle East tensions provide tailwinds for the energy sector.
MPC presents a compelling value opportunity with solid fundamentals and positive analyst sentiment, though investors face risks from volatile oil prices, regulatory scrutiny over pricing practices, and declining revenue trends. The stock trades near analyst consensus target of $278.38 with 76% buy ratings supporting upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
